Michael J. Labarre has sold HALO and made no open-market buys since May 2020
SVP and Chief Technical Officer at Halozyme Therapeutics, Inc.
SEC CIK 0001507174 · Filings on SEC.gov ↗
Every filing
36 filings since May 2020, newest first
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
Halozyme Therapeutics, Inc.
SVP and Chief Technical Officer
About Michael J. Labarre
Michael J. LaBarre is a Person and a biotechnology executive who most recently served as Senior Vice President and Chief Technical Officer at Halozyme Therapeutics, Inc. (HALO), where he was responsible for the company’s technical organization and contributed to the development of its ENHANZE® drug-delivery platform.( Halozyme also previously named him Chief Scientific Officer before later redesignating his leadership role as Chief Technical Officer.(
LaBarre retired from Halozyme in March 2025 after a multi-year career with the company that included leadership roles such as Vice President of Product Development and Vice President of Product Development and Chief Scientific Officer.( His earlier experience includes technical and scientific roles at Biogen Idec, Vical, and Hybritech, and he also served as adjunct faculty in chemistry at San Diego Mesa College. He earned a Ph.D. in Chemistry from the University of Arizona and a B.S. in Chemistry from Long Island University, Southampton Campus.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.